Growing-up hand in hand with robots: Designing and evaluating child-robot interaction from a developmental perspective

Robots are becoming part of children's care, entertainment, education, social assistance and therapy. A steadily growing body of Human-Robot Interaction (HRI) research shows that child-robot interaction (CRI) holds promises to support children's development in novel ways. However, research has shown that technologies that do not take into account children's needs, abilities, interests, and developmental characteristics may have a limited or even negative impact on their physical, cognitive, social, emotional, and moral development. As a result, robotic technology that aims to support children via means of social interaction has to take the developmental perspective into consideration. With this workshop (the third of a series of workshops focusing CRI research), we aim to bring together researchers to discuss how a developmental perspective play a role for smart and natural interaction between robots and children. We invite participants to share their experiences on the challenges of taking the developmental perspective in CRI, such as long-term sustained interactions in the wild, involving children and other stakeholders in the design process and more. Looking across disciplinary boundaries, we hope to stimulate thought-provoking discussions on epistemology, methods, approaches, techniques, interaction scenarios and design principles focused on supporting children's development through interaction with robotic technology. Our goal does not only focus on the conception and formulation of the outcomes in the context of the workshop venue, but also on their establishment and availability for the HRI community in different forms

STAT3 Regulates Monocyte TNF-Alpha Production in Systemic Inflammation Caused by Cardiac Surgery with Cardiopulmonary Bypass

BACKGROUND: Cardiopulmonary bypass (CPB) surgery initiates a controlled systemic inflammatory response characterized by a cytokine storm, monocytosis and transient monocyte activation. However, the responsiveness of monocytes to Toll-like receptor (TLR)-mediated activation decreases throughout the postoperative course. The purpose of this study was to identify the major signaling pathway involved in plasma-mediated inhibition of LPS-induced tumor necrosis factor (TNF)-α production by monocytes. METHODOLOGY/PRINCIPAL FINDINGS: Pediatric patients that underwent CPB-assisted surgical correction of simple congenital heart defects were enrolled (n = 38). Peripheral blood mononuclear cells (PBMC) and plasma samples were isolated at consecutive time points. Patient plasma samples were added back to monocytes obtained pre-operatively for ex vivo LPS stimulations and TNF-α and IL-6 production was measured by flow cytometry. LPS-induced p38 mitogen-activated protein kinase (MAPK) and nuclear factor (NF)-κB activation by patient plasma was assessed by Western blotting. A cell-permeable peptide inhibitor was used to block STAT3 signaling. We found that plasma samples obtained 4 h after surgery, regardless of pre-operative dexamethasone treatment, potently inhibited LPS-induced TNF-α but not IL-6 synthesis by monocytes. This was not associated with attenuation of p38 MAPK activation or IκB-α degradation. However, abrogation of the IL-10/STAT3 pathway restored LPS-induced TNF-α production in the presence of suppressive patient plasma. CONCLUSIONS/SIGNIFICANCE: Our findings suggest that STAT3 signaling plays a crucial role in the downregulation of TNF-α synthesis by human monocytes in the course of systemic inflammation in vivo. Thus, STAT3 might be a potential molecular target for pharmacological intervention in clinical syndromes characterized by systemic inflammation

Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; p = 0.40). There was no significant effect of DMF on any secondary outcome

Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; p = 0.40). There was no significant effect of DMF on any secondary outcome

Sustainable Entrepreneurship Education

This chapter will give a state-of-the-art and integrated understanding of sustainable entrepreneurship education. It will examine its main components including competences, attitude, teaching approaches, the university ecosystem and assessment. The chapter draws on the results of a systematic literature review conducted for the Erasmus + Teaching Entrepreneurship for Sustainability project. The chapter highlights the importance of sustainable entrepreneurship competencies in creating a mindset for change. The need for sustainable entrepreneurs and so-called 'change makers' highlights the importance of sustainable entrepreneurship education, which empowers students through collaborative, experiential and reflective learning to better our world.</p

Ruimte voor binnensport in Gorinchem

Item does not contain fulltext45 p

Ruimte voor sport in Súdwest-Fryslân: Een vraag-aanbodanalyse van buiten- en binnensportaccommodaties in 2016, 2020 en 2030

Item does not contain fulltext60 p